Objective: To assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CVL-231 30 mg once daily (QD) and 20 mg twice daily (BID) in patients with schizophrenia who are experiencing acute exacerbation of psychosis.
Objective: To assess the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of CVL-231 30 mg once daily (QD) and 20 mg twice daily (BID) in patients with schizophrenia who are experiencing acute exacerbation of psychosis.
You are now leaving cerevel.com, a website provided by Cerevel Therapeutics. The content displayed on external websites is not controlled by Cerevel, and Cerevel assumes no responsibility for the information or statements on external websites.